VIVEVE MEDICAL, INC. VIVE Cash Flow

Viveve medical, inc. (VIVE)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net loss
-6,310	-14,817	-7,956	-9,724	-10,029	-13,492	-12,304	-11,516	-12,669	-10,224	-9,615	-10,425	-6,695	-5,820	-4,869	-5,316	-4,106	-3,677	-3,219	-3,006	-2,524	-1,742	-2,505	-1,131	-802	-884	-3,569	7,945	-7,808	-	-	-	-	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts
74	768	75	74	111	76	71	-10	42	-221	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,001	-3,166	-1,443	-6,779	-1,029	-401	-541	-3,787
Income from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	53
Gain on sale of discontinued operations, net of taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	687
Depreciation and amortization
323	358	272	236	311	241	211	184	150	131	130	81	107	33	33	24	21	20	21	19	17	14	13	14	15	30	9	13	13	12	11	12	8	6	-1	2	2
Stock-based compensation
710	766	517	621	496	741	765	776	753	558	487	455	372	358	272	202	188	75	55	48	42	40	114	17	13	20	-10	9	68	111	134	77	222	25	30	63	30
Fair value of warrants issued
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	20	142	99	-228	118	262	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revaluation of fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1	-8	-22	-21	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
127	311	423	444	399	404	400	390	386	287	273	454	35	34	35	342	45	46	49	54	48	48	106	141	123	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of operating lease right-of-use assets and accretion of operating lease liabilities
5	1	-1	-5	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from minority interest in limited liability company
-182	-196	-168	-138	-125	-118	-132	-158	-249	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in assets and liabilities:
Change in fair value of warrant and options liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,113	-3,999	-	-	-	-3,107	64	232	372	-1,476
Change in fair value of convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,177	-1,312	2,194	-757	-1,061	-2,400	-54	376	2	-2,218
Loss on extinguishment of convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-1,283	-	-	-	-	-	-	-	-
Financing costs associated with convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	530
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	95	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	500	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-66	-	-	-	-25
Deferred income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	492
Accounts receivable
-220	-465	-675	-1,148	-815	789	-2,179	232	828	1,159	1,033	-220	1,929	284	1,218	-202	198	354	239	-35	29	-	-	-	-	-0	193	-167	-27	11	79	16	-154	-	-	-	-
Inventory
-313	834	-63	505	-206	-331	387	433	1,497	489	-70	-312	-40	1,313	603	-56	-623	904	308	190	36	-6	-51	-18	-22	-71	21	50	-71	-53	35	-68	30	36	48	-173	17
Prepaid expenses and other current assets
-243	-604	283	-349	559	-122	-344	-278	561	-476	1,329	648	174	-232	94	-338	314	18	-37	892	6	161	-135	40	-25	33	181	-455	483	-46	32	-152	108	-152	-65	159	-8
Other noncurrent assets
-417	0	0	-23	-17	-30	13	-16	2	90	-20	-20	16	3	-6	-7	8	-8	-7	-7	4	126	0	0	-14	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
654	-183	185	-1,078	-1,310	492	-1,365	1,002	-934	1,230	225	-15	273	609	623	225	197	331	489	0	196	-150	-638	161	76	42	384	94	-39	146	-186	287	-19	104	-3	-179	-116
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-197	-69	-77	138	-29	0	-	-	-	-
Accrued and other liabilities
-2,654	1,030	-830	466	-2,202	1,641	-133	1,001	-366	672	1,752	94	-99	261	-78	-352	1,361	466	-165	409	360	-4	39	61	-39	-79	-95	142	-127	96	78	-43	30	5	5	6	-52
Other noncurrent liabilities
-40	-759	56	52	52	240	89	87	86	250	77	-90	37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-5,736	-5,374	-6,608	-7,696	-11,558	-9,845	-10,011	-8,043	-15,191	-8,579	-8,943	-9,282	-8,049	-	-	-	-2,049	-3,866	-3,257	-3,398	-1,674	-1,939	-2,697	-781	-574	-805	-79	-712	-2,158	-	-	-	-949	-	-	-	-915
Cash flows from investing activities:
Proceeds from sale of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of property and equipment
161	239	130	539	179	1,159	180	341	462	95	410	249	151	32	87	101	36	61	47	1	0	-	-	-	-	-	-	-	-	0	0	74	0	-	-	-	-
Net cash used in investing activities
-161	-239	-130	-539	-179	-1,159	-180	-341	-462	-95	-2,910	-249	-151	-	-	-	-36	-61	-47	-1	0	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Proceeds from equity financings, net of issuance costs
-	-	-	-	-	20,385	11	160	33,236	125	0	-63	31,503	0	29	13,857	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transaction costs in connection with November 2019 Offering
30	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	8	6	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of Series A and B common warrants
1,661	-	-	-	-	-	-	-	-	-	-	-	-	0	65	0	27	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from note payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1,000	500	1,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from sale of common stock and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	3,504	-	-	-	-	-	-	-	-
Proceeds from related party convertible bridge notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,750	0	250	-	-	-	-	0	0	0	3,605
Repayments of note payable
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	4,534	299	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common shares from employee stock purchase plan
-	0	1	20	35	45	64	59	65	76	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from related party convertible bridge notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	250	1,050	200	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19,278	-269	5,226	1,003	11,540	1,000	869	4,454	1,050	200	874	-888	0	3,754	-	-	-	-	-	-	-	-
Net cash provided by financing activities
1,631	9,835	6,318	-80	35	20,430	75	219	33,301	10,197	0	9,202	31,503	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,605
Net cash provided by operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-18	228
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	1,000
Net cash provided by discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-18	1,228
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-23	9	-	-	-	-35	64	-39	26	16
Net decrease in cash and cash equivalents
-4,266	4,222	-420	-8,315	-11,702	9,426	-10,116	-8,165	17,648	1,523	-11,853	-329	23,303	-5,925	-5,920	14,925	-2,354	1,299	-2,301	8,141	-674	-1,081	1,757	163	-374	69	-958	-735	1,605	-	-	-	-984	-589	-885	-1,199	3,934
Supplemental disclosure:
Cash paid for interest
-	441	703	689	675	682	676	662	653	447	436	989	194	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	149	423	64	45	66	50	35	32	47	35	35	34	-5	50	62	63	54	50	50	49	50	50	22
Cash paid for income taxes
-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	1	0	0	0	0	1	0	0	0	1	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of cash flow information as of end of period:
Issuance of Series B convertible preferred stock in settlement of dividends
989	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted stock awards granted to employees for 2015 accrued bonuses
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	246	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashless settlement of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,159	844	-	-	-	-	-	-	-	-
Issuance of note payable in settlement of accrued interest
126	253	331	324	318	322	318	311	305	210	285	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net transfer of equipment between inventory and property and equipment
89	-7	510	-342	46	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted stock awards granted to employees for 2015 accrued bonuses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net transfer of equipment between inventory and property and equipment
-	-	-	-	-	-	-	-	59	2	70	28	264	39	35	25	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating cash outflows from operating leases
75	75	147	0	73	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right-of-use assets obtained in exchange for operating lease liabilities (upon adoption of ASC 842)
-	0	0	0	629	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	3,208